Bimekizumab shows benefits in treating axSpA at 1 year in trials
A year of treatment with bimekizumab was safe and significantly eased symptoms of axial spondyloarthritis (axSpA) in participants from two Phase 3 clinical trials, data show. “Results at [one year] from the BE MOBILE trials suggest that [bimekizumab] is an effective treatment option resulting in sustained efficacy across…